A stable composition containing IL-2, IFN-alpha, beta or gamma or EGF and being free from any warm-blooded animal-origin components such as human, swine or bovine serum albumin or carnitine is produced. A composition containing at least one of IL-2, IFN-alpha, beta and gamma and EGF, a saccharide and/or a sugar alcohol and an amino acid optionally together with an acid and a base and, if needed, a surfactant shows little decrease in the content of the drug component during storage over a prolonged period of time. By putting the composition is a silicone-coated container, the decrease in the drug content can be further prevented.
